NK-cells play an important role in the innate immune response to multiple myeloma (MM) and are known to contribute to the efficacy of novel therapeutics. We, therefore, utilized a MM-based model system to generate proof-of concept data demonstrating antibody-mediated NK-cell retargeting to cell...
"We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma""SIM0500 is developed via Simcere Zaiming's proprie...
Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet med...
L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921–3933 (2019). Article CAS PubMed Google Scholar Harbeck, N. et al. HER2 dimerization inhibitor ...
It also includes multiple myeloma (MM) cells, and a lumped species representing all CD38 + PBMCs, such as B-cells, NK cells and monocytes. The key interaction represented in this system is the formation of synapses between cells connected by the CD38xCD28xCD3 trispecific antibody (see ...
Here, we demonstrate that Myeloma Drug Sensitivity Testing (My-DST) can measure efficacy of TCE antibodies ex vivo in primary MM harnessing the patients’ own endogenous immune cells. This allows the study of TCE antibody sensitivity in a setting that can recapitulate the immune exhaustion often ...
Despite recent breakthrough in the treatment of multiple myeloma (MM) relapses are frequent, highlighting the need for novel approaches. Here we describe a novel anti-CD38/CD28xCD3 trispecific T cell engager (TCE) that targets CD38 expre... N El-Murr,S Kassem,N Carrié,... - 《Cancer Re...
Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet me...
Cancer immunotherapy goes trispecificCancer immunotherapyImmunotherapyA trispecific antibody that provides T cell co-stimulation shows promise in preclinical models of myeloma.doi:10.1038/s41577-019-0255-zAlexandra FlemmingNature Reviews Immunology
AbbVie MORE ON THIS TOPIC Lymphoma Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’ February 27, 2025 · 2 min read · Tristan Manalac Cancer AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Dru...